MannKind

Contributing Author

Recent Articles by MannKind

Jun-05	Data at ADA 2026 Highlights Key Findings from Clinical and Real-World Studies of MannKind's Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems MNKD GlobeNewswire
Jun-03	MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF MNKD GlobeNewswire
May-29	MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval MNKD -6.37% MNKD GlobeNewswire
May-29	MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes MNKD -6.37% MNKD GlobeNewswire
May-27	MannKind to Present at Jefferies Global Healthcare Conference MNKD GlobeNewswire
May-27	MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems MNKD GlobeNewswire
May-06	MannKind Reports First Quarter 2026 Financial Results and Provides Business Update MNKD +24.48% GlobeNewswire
May-06	MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases MNKD +24.48% GlobeNewswire
Apr-29	MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 MNKD GlobeNewswire
Mar-09	MannKind to Present New Data From Pediatric and Adult Studies of Afrezza at ATTD 2026 MNKD GlobeNewswire
Mar-05	MannKind Announces Settlement of Convertible Senior Notes MNKD -7.77% MNKD GlobeNewswire
Mar-04	MannKind to Participate in Upcoming Investor Conferences MNKD GlobeNewswire
Feb-26	MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update MNKD -7.43% GlobeNewswire
Feb-19	MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference MNKD GlobeNewswire
Feb-18	MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 MNKD GlobeNewswire
Feb-09	MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) MNKD GlobeNewswire
Jan-26	MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy MNKD GlobeNewswire
Jan-08	MannKind Provides Business Updates and 2026 Growth Drivers MNKD GlobeNewswire
Dec-23	MannKind Shares FUROSCIX Business Updates MNKD GlobeNewswire
Dec-01	MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease MNKD GlobeNewswire
Nov-11	MannKind to Present at the Jefferies Global Healthcare Conference MNKD GlobeNewswire
Nov-10	MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease MNKD GlobeNewswire
Nov-06	MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes MNKD -5.94% GlobeNewswire
Nov-05	MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update MNKD +10.58% GlobeNewswire
Oct-29	MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025 MNKD GlobeNewswire
Oct-13	MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes MNKD GlobeNewswire
Oct-07	MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care MNKD GlobeNewswire
Sep-29	MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer MNKD GlobeNewswire
Aug-27	MannKind to Present at Upcoming Investor Conferences MNKD +11.06% GlobeNewswire
Aug-27	MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy MNKD +11.06% GlobeNewswire
Aug-25	MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases MNKD -5.11% GlobeNewswire
Aug-06	MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement MNKD -13.16% GlobeNewswire
Aug-06	MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update MNKD -13.16% GlobeNewswire
Jul-30	MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025 MNKD GlobeNewswire
Jun-09	MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23 MNKD -10.30% MNKD GlobeNewswire
May-27	INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29 MNKD GlobeNewswire
May-13	MannKind to Present at Upcoming Investor Conferences MNKD GlobeNewswire
May-08	MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update MNKD GlobeNewswire
May-01	MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 MNKD GlobeNewswire

MannKind

Recent Articles by MannKind

Upgrade your Finviz experience